Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Lasofoxifene shows promise for women with ESR1-mutated mBC

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

New data presented at ESMO for multi-cancer early detection

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence

Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer

Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma